Patents by Inventor Yvette Stallwood

Yvette Stallwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9290563
    Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: March 22, 2016
    Assignee: Lonza Biologics PLC
    Inventors: Andreas Arnell, Jose Jimenez, Rebecca Michael, Yvette Stallwood, Jesus Zurdo
  • Publication number: 20150104449
    Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.
    Type: Application
    Filed: January 5, 2015
    Publication date: April 16, 2015
    Inventors: Andreas Arnell, Jose Jimenez, Rebecca Michael, Yvette Stallwood, Jesus Zurdo
  • Patent number: 8951516
    Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: February 10, 2015
    Assignee: Lonza Biologics PLC
    Inventors: Andreas Arnell, Jose Jimenez, Rebecca Michael, Yvette Stallwood, Jesus Zurdo
  • Publication number: 20120148568
    Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.
    Type: Application
    Filed: August 20, 2010
    Publication date: June 14, 2012
    Applicant: LONZA BIOLOGICS PLC
    Inventors: Andreas Arnell, Jose Jimenez, Rebecca Michael, Yvette Stallwood, Jesus Zurdo
  • Publication number: 20090286745
    Abstract: This invention relates to the inhibition of alpha-synuclein aggregation using peptidyl compounds which are retroenantiomers of the alpha-synuclein sequence, in particular retroenantiomers of sequences in the regions between residues 1 to 60 or residues 61 to 96. Peptidyl compounds of the invention may optionally be coupled to doperminergic targeting moieties and/or blood brain barrier transport moieties and may be useful in the treatment of alpha-synucleinopathies such as Parkinson's disease.
    Type: Application
    Filed: July 2, 2007
    Publication date: November 19, 2009
    Inventors: Jesus Zurdo, Susan Fowler, Yvette Stallwood, Ernest Giralt, Meritxell Teixido, Natalia Carulla
  • Publication number: 20070093440
    Abstract: An RNAi agent targets a component of a human Notch signalling pathway other than presenilin1 or presenilin2 by RNA interference to reduce expression of said component.
    Type: Application
    Filed: July 27, 2006
    Publication date: April 26, 2007
    Inventors: Brian Champion, Grahame McKenzie, Yvette Stallwood